Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Milnacipran in Patients With Fibromyalgia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male subjects who fulfill the American College of Rheumatology's case definition for Fibromyalgia.~* 18 through 68 years of age~Exclusion Criteria:~* Pregnant or trying to become pregnant~* Taking any other Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or already taking milnacipran~* Patients who do not indicate their pain levels as less than substantial despite their best care~* History of any psychotic disorder or history of alcoholism or drug abuse within 10 years of intake as determined by psychiatric diagnostic interview~* Presence of current depression as determined by psychiatric diagnostic interview~* Presence of brain lesion on MRI anatomical study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 68 Years
- Healthy Volunteers: f

Study Arms:
- Patients taking the drug Milnacipran (Type: ACTIVE_COMPARATOR): Randomize patients signing informed consent and give 50% of them Milnacipran -- blinded to the investigators.
- Patients taking the placebo (Type: PLACEBO_COMPARATOR): Randomize patients signing informed consent and give 50% of them the placebo -- blinded to the investigators.

Based on this trial design, predict the completion outcome and termination type (if applicable).